Literature DB >> 17456750

Pathophysiology of sepsis.

Daniel G Remick1.   

Abstract

Sepsis remains a critical problem with significant morbidity and mortality even in the modern era of critical care management. Multiple derangements exist in sepsis involving several different organs and systems, although controversies exist over their individual contribution to the disease process. Septic patients have substantial, life-threatening alterations in their coagulation system, and currently, there is an approved therapy with a component of the coagulation system (activated protein C) to treat patients with severe sepsis. Previously, it was believed that sepsis merely represented an exaggerated, hyperinflammatory response with patients dying from inflammation-induced organ injury. More recent data indicate that substantial heterogeneity exists in septic patients' inflammatory response, with some appearing immuno-stimulated, whereas others appear suppressed. Cellular changes continue the theme of heterogeneity. Some cells work too well such as neutrophils that remain activated for an extended time. Other cellular changes become accelerated in a detrimental fashion including lymphocyte apoptosis. Metabolic changes are clearly present, requiring close and individualized monitoring. At this point in time, the literature richly illustrates that no single mediator/system/pathway/pathogen drives the pathophysiology of sepsis. This review will briefly discuss many of the important alterations that account for the pathophysiology of sepsis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456750      PMCID: PMC1854939          DOI: 10.2353/ajpath.2007.060872

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  85 in total

Review 1.  Neutrophils, host defense, and inflammation: a double-edged sword.

Authors:  J A Smith
Journal:  J Leukoc Biol       Date:  1994-12       Impact factor: 4.962

2.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

3.  Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.

Authors:  C J Fisher; S M Opal; J F Dhainaut; S Stephens; J L Zimmerman; P Nightingale; S J Harris; R M Schein; E A Panacek; J L Vincent
Journal:  Crit Care Med       Date:  1993-03       Impact factor: 7.598

4.  Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors:  C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal:  Crit Care Med       Date:  1994-01       Impact factor: 7.598

5.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial.

Authors:  D J Dries; G J Jurkovich; R V Maier; T P Clemmer; S N Struve; J A Weigelt; G G Stanford; D L Herr; H R Champion; F R Lewis
Journal:  Arch Surg       Date:  1994-10

6.  Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis.

Authors:  M A Boermeester; P A van Leeuwen; S M Coyle; G J Wolbink; C E Hack; S F Lowry
Journal:  Arch Surg       Date:  1995-07

Review 7.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

8.  Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture.

Authors:  K M McMasters; J C Peyton; D J Hadjiminas; W G Cheadle
Journal:  Cytokine       Date:  1994-09       Impact factor: 3.861

9.  CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.

Authors:  J F Dhainaut; J L Vincent; C Richard; P Lejeune; C Martin; L Fierobe; S Stephens; U M Ney; M Sopwith
Journal:  Crit Care Med       Date:  1995-09       Impact factor: 7.598

10.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Authors:  E Abraham; R Wunderink; H Silverman; T M Perl; S Nasraway; H Levy; R Bone; R P Wenzel; R Balk; R Allred
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

View more
  172 in total

1.  Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A-/- mice.

Authors:  Akhil Hegde; Ramasamy Tamizhselvi; Jayapal Manikandan; Alirio J Melendez; Shabbir M Moochhala; Madhav Bhatia
Journal:  Mol Med       Date:  2010-02-08       Impact factor: 6.354

2.  Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; Y Fan; M M Kahl-McDonagh; T A Ficht
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

3.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

4.  Rho kinases (ROCKs) in sepsis-induced acute lung injury.

Authors:  Ravin Narain
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

Review 5.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

6.  Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice.

Authors:  Bryan Belikoff; Stephen Hatfield; Michail Sitkovsky; Daniel G Remick
Journal:  Shock       Date:  2011-04       Impact factor: 3.454

Review 7.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 8.  Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.

Authors:  Philip R Mayeux; Lee Ann MacMillan-Crow
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

9.  The role of the mitochondrial glycine cleavage complex in the metabolism and virulence of the protozoan parasite Leishmania major.

Authors:  David A Scott; Suzanne M Hickerson; Tim J Vickers; Stephen M Beverley
Journal:  J Biol Chem       Date:  2007-11-02       Impact factor: 5.157

10.  Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis.

Authors:  Kavin G Shah; Rongqian Wu; Asha Jacob; Steven A Blau; Youxin Ji; Weifeng Dong; Corrado P Marini; Thanjavur S Ravikumar; Gene F Coppa; Ping Wang
Journal:  Mol Med       Date:  2009-09-18       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.